



## Online Supplementary Figure 1 Over-time profile of the usage of oral hypoglycemic agents




Online Supplementary Figure 2 Kaplan-Meier analysis of microvascular complications

A Retinopathy




Group A	N	3395	3214	3049	2858	2698	2511	1803	2	0
Group B	N	1755	1671	1565	1474	1385	1308	949	1	0

B Nephropathy




Group A	N	3395	3207	3040	2853	2689	2507	1802	2	0
Group B	N	1755	1665	1553	1459	1367	1287	934	1	0

C Neuropathy



Group A	N	3395	3213	3058	2879	2719	2538	1819	2	0
Group B	N	1755	1672	1567	1480	1392	1314	956	1	0

Online Supplementary Figure 3 Over-time changes of HbA1c



Group A	N	2903	3057	2615	2327	2070	1782	1074
Group B	N	1438	1418	1107	914	780	668	382

## Legends for Online Supplementary Figures

### **Online Supplementary Figure 1 Over-time profile of the usage of oral hypoglycemic agents**

OHA usage was profiled over time as the percentage (%) of individual drug class used in the patients at each visit. Note Group A patients mostly (90% or more) continued to use alogliptin (or other DPP-4 inhibitors), while in Group B, a majority (60-70%) of patients continued to use biguanides, and the use of DPP-4 inhibitors gradually increased (up to ~36%) becoming second dominant at the later stage of the study.

DPP-4, dipeptidyl peptidase-4; OHA, oral hypoglycemic agent.

### **Online Supplementary Figure 2 Kaplan-Meier analysis of microvascular complications**

(A) Retinopathy, (B) Nephropathy and (C) Neuropathy.

A combination of 'onset' and 'progression' was analyzed. Between-group comparisons were performed by long-rank test.

### **Online Supplementary Figure 3 Over-time changes of HbA1c**

Measurements (mean  $\pm$  SD) were plotted against each visit. Between-group comparisons were performed by 2-sample t test, and statistical significance is represented as \*\*\*P<0.001 at baseline, and then P=0.204, \*P=0.015, \*\*\*P<0.001, \*\*P=0.001, \*\*P=0.002, and \*\*\*P<0.001, respectively.

SD, standard deviation.